KKKatsuyuki Kiura

Katsuyuki Kiura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katsuyuki Kiura has a total of 670 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment

    by Atsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, Sachi Okawa, Takamasa Nakasuka, Kazuya Nishii, Jun Nishimura, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, et al.

    Immune checkpoint inhibitors (ICIs) show limited efficacy in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma due to its non-inflamed tumor microenvironment (TME). While quadruple therapy combining chemotherapy, anti-programmed death-ligand 1 (PD-L1), and anti-vascular endothelial growth factor (VEGF) antibodies has shown inconsistent results in EGFR-tyrosine kinase inhibitor (TKI)-pretreated patients, whether anti-VEGF therapy can modulate the intrinsic non-inflamed TME remains unknown. We employed an EGFR-TKI-naïve syngeneic Egfr-mutant mouse model and evaluated effects of anti-VEGF, anti-PD-L1, carboplatin, and paclitaxel as monotherapies and combinations, with TME analysis via immunohistochemistry (IHC), flow cytometry, and RNA sequencing. Anti-PD-L1 showed no antitumor effect, and adding anti-VEGF failed to convert the TME to an inflamed status. Although paclitaxel—but not carboplatin—combined with low-dose anti-VEGF inhibited tumor growth, adding anti-PD-L1 provided no benefit, indicating the anti-VEGF-A antibody evaluated here has a limited role in sensitizing tumors to anti-PD-L1 regardless of chemotherapy. CD8+ T-cell depletion did not attenuate the effect of paclitaxel plus low-dose anti-VEGF, and IHC and RNA sequencing revealed increased natural killer cell infiltration, suggesting a CD8+ T-cell-independent, innate immune mechanism. These findings provide preclinical evidence that the evaluated anti-VEGF has limited immunomodulatory activity in EGFR-TKI-naïve Egfr-mutant tumors with a non-inflamed TME, and suggest immunotherapeutic strategies beyond CD8+ T-cell-mediated immunity warrant investigation.

  • Open Access

    Supplementary Figure S4 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Supplementary Figure S4 (A) Representative images of F4/80, CD206, CDF1-R, and CD11c IHC staining in Egfr-mutant lung tumors after 2 weeks of treatment with osimertinib 15 mg/kg 7 days/week or osimertinib 15 mg/kg plus pexidartinib 50 mg/kg 7 days/week) (n = 6) for 14 days. (Magnification: ×100. Scale bars: 100 μm). Data are representative of two independent experiments with similar results. (B) Syngeneic lung cancer mouse model was treated with osimertinib 15 mg/kg 7 days/week, pexidartinib 50 mg/kg 7 days/week, osimertinib 15 mg/kg plus pexidartinib 50 mg/kg 7 days/week, and vehicle for 14 days. Body weight loss was not observed in the mice. (n = 6 tumors per group, 3 mice per group). Bars indicate the mean ± standard error. ns, not significant.

  • Open Access

    Supplementary Figure S2 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Supplementary Figure S2 (A) Representative images of FOXP3 IHC staining in Egfr-mutant lung tumors after 2 weeks of treatment with osimertinib 15 mg/kg p.o. or gefitinib 50 mg/kg p.o.). (Magnification: ×100; Scale bars: 100 μm). Data are representative of two independent experiments with similar results. (B) Foxp3+ areas were quantified using ImageJ software. Data are representative of two independent experiments with similar results. Data are presented as the mean ± SE (n = 5 field-of-view per group; Magnification: ×100). Bars indicate the mean ± standard error. (ns, not significant; t-test). (C) Cytokine array of Egfr-mutant lung tumors from mice treated with gefitinib (50 mg/kg) for 14 days. (D) Quantification of F4/80 and CD206-positive cells in the immunohistochemical staining shown in Figure 3F was performed using the ImageJ software. Data are representative of two independent experiments with similar results. Data are presented as the mean ± standard error (SE) (n = 5 field-of-view per group; Magnification: ×100). Bars indicate the mean ± SE. (ns, not significant; **, P<0.01, ***, P<0.001, ****, P <0.0001, one-way ANOVA with post-hoc Tukey’s test). pre, pre-treatment; ns, not significant.

  • Open Access

    Data from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Persister cancer cells, which reversibly adapt to survive EGFR–tyrosine kinase inhibitor (TKI) treatment, contribute to the incurability of EGFR-mutant lung cancer. We previously reported that gefitinib induces CD8+ T cell–related tumor immunity in a genetically engineered mouse model. This study investigates the tolerance of persister cancer cells to EGFR-TKI–induced tumor immunity in this model. EGFR-mutated lung cancer cells (C57BL/6/EgfrdelE748-A752) from the genetically engineered mouse model were transplanted subcutaneously into wild-type C57BL/6J mice. Persistent tissues under osimertinib treatment were analyzed using digital spatial transcriptional profiling, IHC staining, and flow cytometry. The antitumor effect of osimertinib peaked at 14 days, leaving a small population of persister cancer cells. The number of PD-1+ CD8+ cells increased in the tumor microenvironment (TME), and CD8+ cell depletion attenuated the antitumor effect of osimertinib. Digital spatial transcriptional profiling revealed upregulated expression of M2 macrophage–related genes in the TME of persister cancer cells. Consistently, IHC and flow cytometry confirmed an increased number of CD206+ macrophages in the TME. Combining osimertinib with the colony-stimulating factor-1 receptor inhibitor pexidartinib reduced CD206+ macrophages and enhanced the efficacy of osimertinib. Elevated Granzyme B or CD107 expression on CD8+ cells in the TME suggests that macrophages negatively affect osimertinib-induced antitumor immunity. M2-like macrophages may contribute to the immune tolerance of persister cancer cells against EGFR-TKI–induced tumor immunity. A clinical trial evaluating combined osimertinib and colony-stimulating factor-1 receptor inhibitor therapy is warranted for EGFR-mutated lung cancer.

  • Open Access

    Supplementary Figure S1 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Supplementary Figure S1 (A) Tumor growth in the syngeneic Egfr-mutant lung cancer model treated with osimertinib at the indicated dose for 14 days and subsequently observed for 4 days. Osimertinib (5, 10, or 15 mg/kg p.o. 7 days/week). (n = 6 tumors per group, 3 mice per group). Bars indicate the mean ± standard error. (B) Tumor growth in the Egfr-mutant lung cancer model. The mice were treated with osimertinib (15 mg/kg, p.o., 7 days/week) for 28 days, after which osimertinib was re-administered. Data are representative of two independent experiments with similar results. (C) Representative images of EGFR IHC staining in Egfr-mutant lung tumors treated with EGFR-TKI (osimertinib 15 mg/kg, oral administration) for pre-treatment (pre), 4, 14 days, and 4 weeks. (Magnification: ×100. Scale bar: 100 μm).

  • Open Access

    Supplementary Figure S3 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Supplementary Figure S3 (A) Representative flow cytometric analysis of MHC class II and CD206 expression of tumor-associated macrophages (TAMs) defined as CD45+/CD3−/CD11b+/F4/80+. The gates indicate a strategy for defining M1 and M2 TAMs. (B) Quantification of F4/80, CD206, CSF1-R and CD8-positive cells in the immunohistochemical staining shown in Figure 4A was performed using the ImageJ software. Data are representative of two independent experiments with similar results. Data are presented as the mean ± standard error (SE) (n = 5 field-of-view per group; Magnification: ×100). Bars indicate the mean ± SE. (ns, not significant; *, P< 0.05, **, P<0.01, ***, P<0.001, ****, P <0.0001, one-way ANOVA with post-hoc Tukey’s test). ns, not significant.

  • Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation

    by Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, Jun Nishimura, Takamasa Nakasuka, Atsuko Hirabae, Naofumi Hara, Hirofumi Inoue, Go Makimoto, Kiichiro Ninomiya, et al.

    Persister cancer cells, which reversibly adapt to survive EGFR–tyrosine kinase inhibitor (TKI) treatment, contribute to the incurability of EGFR-mutant lung cancer. We previously reported that gefitinib induces CD8+ T cell–related tumor immunity in a genetically engineered mouse model. This study investigates the tolerance of persister cancer cells to EGFR-TKI–induced tumor immunity in this model. EGFR-mutated lung cancer cells (C57BL/6/EgfrdelE748-A752) from the genetically engineered mouse model were transplanted subcutaneously into wild-type C57BL/6J mice. Persistent tissues under osimertinib treatment were analyzed using digital spatial transcriptional profiling, IHC staining, and flow cytometry. The antitumor effect of osimertinib peaked at 14 days, leaving a small population of persister cancer cells. The number of PD-1+ CD8+ cells increased in the tumor microenvironment (TME), and CD8+ cell depletion attenuated the antitumor effect of osimertinib. Digital spatial transcriptional profiling revealed upregulated expression of M2 macrophage–related genes in the TME of persister cancer cells. Consistently, IHC and flow cytometry confirmed an increased number of CD206+ macrophages in the TME. Combining osimertinib with the colony-stimulating factor-1 receptor inhibitor pexidartinib reduced CD206+ macrophages and enhanced the efficacy of osimertinib. Elevated Granzyme B or CD107 expression on CD8+ cells in the TME suggests that macrophages negatively affect osimertinib-induced antitumor immunity. M2-like macrophages may contribute to the immune tolerance of persister cancer cells against EGFR-TKI–induced tumor immunity. A clinical trial evaluating combined osimertinib and colony-stimulating factor-1 receptor inhibitor therapy is warranted for EGFR-mutated lung cancer.


  • Open Access

    Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

    by Masataka Taoka, Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Akiko Sato, Naohiro Oda, Hirohisa Kano, Kayo Nakamura, Haruyuki Kawai, et al.

    Background: Limited data are available on the frequency and significance of body weight loss during cancer therapy. This study investigated the frequency of patients who experienced body weight loss during immune checkpoint inhibitor (ICI) plus chemotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of weight loss on treatment outcomes. Methods: Using the clinical data of 370 patients with NSCLC who received a combination of ICI and chemotherapy at 13 institutions, this study investigated the frequency of body weight loss > 5% during treatment and determined the impact of body weight loss on patient outcomes. Results: Of the 370 included patients, 141 (38.1%) lost more than 5% of their body weight during ICI plus chemotherapy (WL group). The 2-month landmark analysis showed that patients who experienced body weight loss of >5% during treatment had worse overall survival (OS) and progression-free survival (PFS) than those who did not (OS 14.0 and 31.1 months in the WL non-WL groups, respectively, p < 0.001; PFS 6.8 and 10.9 months in the WL non-WL groups, respectively, p = 0.002). Furthermore, a negative impact of body weight loss on survival was observed even in those who had obesity (body mass index [BMI] ≥ 25.0) at the start of therapy (OS 12.8 and 25.4 months in the WL non-WL groups, respectively, p < 0.001; PFS 5.7 and 10.7 months in the WL non-WL groups, respectively, p = 0.038). Conclusions: In conclusion, weight loss of >5% during ICI plus chemotherapy negatively influenced patient outcomes. Further and broader studies should investigate the role of nutritional status, specifically weight change and nutritional support, in responsiveness to ICI plus chemotherapy.


  • Open Access

    A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)

    by Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, et al.

    Bevacizumab with platinum doublet therapy including paclitaxel + carboplatin improves the survival of patients with non-squamous non-small cell lung cancer. However, in a previous trial (CA031), paclitaxel + carboplatin led to Grade > 3 neutropenia in a Japanese population. Nanoparticle albumin-bound paclitaxel exhibits an improved toxicity profile. We evaluated the safety, dosage and response rate of the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination in a Japanese population. Chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer were included. The dosage schedule was established in the Phase I trial as follows: 4–6 cycles of carboplatin (area under the concentration–time curve = 6 on Day 1) + nanoparticle albumin-bound paclitaxel (100 mg/m2 on Days 1, 8 and 15) + bevacizumab (15 mg/kg on Day 1), followed by maintenance therapy (nanoparticle albumin-bound paclitaxel + bevacizumab). The response rate and presence of adverse effects were evaluated in the Phase II trial. The overall response rate was 56.5% (90% confidence interval: 44.5–68.5), and 93% of patients (43/46) showed tumor shrinkage or maintained a stable disease course. The primary endpoint was achieved. At the median follow-up duration of 42 months, the median overall survival was 18.9 (range: 10.5–32.4) months. The most frequently observed Grade ≥ 3 adverse effects were neutropenia (72%), leukopenia (50%) and anemia (30%). All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.


  • Open Access

    Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study

    by Hisao Higo, Hirohisa Ichikawa, Yukako Arakawa, Yoshihiro Mori, Junko Itano, Akihiko Taniguchi, Satoru Senoo, Goro Kimura, Yasushi Tanimoto, Kohei Miyake, et al.

    Background: Dupilumab is a fully humanized monoclonal antibody that blocks interleukin-4 and interleukin-13 signals. Several large clinical trials have demonstrated the efficacy of dupilumab in patients with severe asthma. However, few studies have examined a switch to dupilumab from other biologics. Methods: This retrospective, multi-center observational study was conducted by the Okayama Respiratory Disease Study Group. Consecutive patients with severe asthma who were switched to dupilumab from other biologics without a treatment interval between May 2019 and September 2021 were enrolled. Patients with a treatment interval of more than twice the standard dosing interval for the previous biologic prior to dupilumab administration were excluded. Results: The median patient age of the 27 patients enrolled in this study was 57 years (IQR, 45–68 years). Eosinophilic chronic rhinosinusitis (ECRS)/chronic rhinosinusitis with nasal polyp (CRSwNP) was confirmed in 23 patients. Previous biologics consisted of omalizumab (n = 3), mepolizumab (n = 3), and benralizumab (n = 21). Dupilumab significantly improved FEV1 (median improvement: +145 mL) and the asthma control test score (median improvement: +2). The overall response rate in patients receiving dupilumab for asthma as determined using the Global Evaluations of Treatment Effectiveness (GETE) was 77.8%. There were no significant differences in the baseline characteristics of the GETE-improved group vs. the non-GETE-improved group. ECRS/CRSwNP improved in 20 of the 23 patients (87.0%). Overall, 8 of the 27 patients (29.6%) developed transient hypereosinophilia (>1500/μL), but all were asymptomatic and able to continue dupilumab therapy. Conclusions: Dupilumab was highly effective for the treatment of severe asthma and ECRS/CRSwNP, even in patients switched from other biologics without a treatment interval.